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Introduction {#s1}
============

Chronic kidney disease (CKD) has been recognized as a worldwide health issue [@pone.0108862-Nugent1]. The pathophysiological mechanisms of renal function progression in CKD have still not been completely explored. In addition to well-known traditional risk factors, non-traditional risk factors, such as endothelial dysfunction, which might lead to cell apoptosis, vascular regression and renal fibrosis, have gradually attracted physicians\' attention [@pone.0108862-Chang1].

The angiopoietin (Ang)/Tie ligand-receptor system tightly controls the endothelial phenotype during angiogenesis and vascular inflammation [@pone.0108862-Brindle1]. Among the members of Ang family, Ang-1 and Ang-2 have attracted much attention [@pone.0108862-Fam1]. Ang-1-driven Tie2 phosphorylation maintains structure integrity of vasculature, and protects the endothelium from excessive activation by cytokines and growth factors [@pone.0108862-Fiedler1]. On the other hand, Ang-2 is expressed in endothelial cells, and stored in Weibel-Palade bodies (WPB) [@pone.0108862-Fiedler2]. The rapid release of Ang-2 from endothelial cells upon activation of the endothelium by hypoxia, histamine, and thrombin would disrupt the protective, constitutive Ang-1/Tie2 signaling by preventing Ang-1 from binding to the receptor [@pone.0108862-Fiedler1], [@pone.0108862-Huang1]. Consequently, the loss of Tie2 signaling destabilizes the endothelium and contributes to angiogenic or inflammatory response to cytokines and growth factors [@pone.0108862-Fiedler3].

Increased circulating Ang-2 has been found in diabetes mellitus [@pone.0108862-Lim1], arterial hypertension [@pone.0108862-Nadar1], congestive heart failure [@pone.0108862-Chong1], peripheral artery disease [@pone.0108862-David1], coronary artery disease [@pone.0108862-Lee1], sepsis [@pone.0108862-Parikh1], critical illness [@pone.0108862-Kumpers1], and acute kidney injury [@pone.0108862-Kumpers2]. Additionally, accumulating evidence shows that circulating Ang-2 is also markedly elevated in CKD and dialysis patients [@pone.0108862-David2]. Elevated Ang-2 levels are also correlated with long-term mortality in patients with CKD stage 4 and on dialysis [@pone.0108862-David3]. Although Ang-2 is associated with microalbuminuria [@pone.0108862-Chang2], a clinical marker of renal injury, the relationship between Ang-2 and renal progression has not been well-explored in CKD patients not on dialysis. This study tries to analyze whether Ang-2 is associated with renal outcome, including reaching commencing dialysis and rapid decline in renal function (estimated glomerular filtration rate (eGFR) decline per year), in patients with CKD stages 3--5.

Materials and Methods {#s2}
=====================

Study Participants {#s2a}
------------------

This observational study was conducted at a tertiary hospital in Southern Taiwan. Six hundred and twenty-one patients with CKD stages 3--5, who had follow-up for one year at least in our integrated CKD program, were enrolled in the study from January 2006 to December 2011. CKD was staged according to K/DOQI definitions and the eGFR was calculated using the equation of the 4-variable Modification of Diet in Renal Disease (MDRD) Study (CKD stage 3, eGFR: 30--59 ml/min/1.73 m^2^; CKD stage 4, eGFR: 15--29 ml/min/1.73 m^2^; CKD stage 5, eGFR \<15 ml/min/1.73 m^2^) [@pone.0108862-Levey1].

Ethics Statement {#s2b}
----------------

The study protocol was approved by the Institutional Review Board of the Kaohsiung Medical University Hospital (KMUH-IRB-990198). Informed consents were obtained in written form from patients and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

Data Collection {#s2c}
---------------

Demographic and clinical data were obtained from medical records and interviews with patients at enrollment. The participant was asked to fast for at least 12 hours before blood sample collection for the biochemistry study and protein in urine was measured using urine protein-creatinine ratio. Patients were classified as diabetic by history and blood glucose values using the American Diabetes Association criteria, oral hypoglycemia agent use, or insulin use. Hypertension was defined as those with a history, or antihypertensive drugs use. Heart disease was defined as a history of heart failure, acute or chronic ischemic heart disease, or myocardial infarction. Cerebrovascular disease was defined as a history of cerebral infarction or hemorrhage. Information regarding patient medications including β-blocker, calcium channel blockers, angiotensin converting enzyme inhibitors (ACEI), and angiotensin II receptor blockers (ARB) before and after enrollment was obtained from medical records.

Quantification of circulating Angiopoietin-2 {#s2d}
--------------------------------------------

Plasma Angiopoietin-2 was measured in duplicate using commercial enzyme-linked immunosorbent assays (R&D Systems Inc, Minneapolis, MN) according to the instructions of the manufacturer. The sensitivity of Ang-2 assay was 1.20 pg/ml. Intraassay and interassay coefficients of variation of Ang-2 were 1.8% and 1.2%, respectively.

Renal Outcomes {#s2e}
--------------

Patients were contacted at outpatient clinics at 3-month intervals to ascertain the clinical status. Renal outcomes included commencing dialysis, doubling creatinine and rapid decline in renal function. Commencing dialysis was defined as requiring maintenance hemodialysis and peritoneal dialysis and confirmed by reviewing medical charts or catastrophic illness certificate (issued by the Bureau of National Health Insurance in Taiwan). The timing for commencing dialysis was considered according to the regulations of the Bureau of the National Health Insurance of Taiwan regarding eGFR, uremic status, nutritional status, and the laboratory data. The timing for doubling creatinine was considered based on all creatinine values from enrollment to the end of the observation period. The decline in renal function was assessed by the eGFR slope, defined as the regression coefficient between eGFR and time in units of ml/min per 1.73 m^2^ per year. All eGFR values available from enrollment to the end of the observation period were included for calculation. At least three eGFR values were required to estimate the eGFR slope. Rapid decline in renal function was defined as the eGFR slope greater than 5 ml/min/1.73 m^2^ per year based on Kidney Disease: Improving Global Outcomes (KDIGO) suggestion [@pone.0108862-Levin1]. Patients were censored at death, last contact, or the end of observation in October 2013.

Statistical Analysis {#s2f}
--------------------

Baseline characteristics of all subjects were stratified by quartiles of Ang-2, cut at 1494.1, 1948.8, and 2593.1 pg/ml. Continuous variables were expressed as mean ±SD or median (25^th^, 75^th^ percentile), as appropriate, and categorical variables were expressed as percentages. Skewed distribution continuous variables were log-transformed to approximate normal distribution. The significance of differences in continuous variables between groups was tested using one-way analysis of variance (ANOVA) or the Kruskal-Wallis H test, as appropriate. The difference in the distribution of categorical variables was tested using the Chi-square test. Kaplan-Meier survival analysis was used to test Ang-2 as a predictor of the risk of composite outcomes either commencing dialysis or doubling creatinine. Cox regression models were applied to examine the relationship between Ang-2 and composite outcomes either commencing dialysis or doubling creatinine. Multivariable logistic regression models were also used to evaluate the association of Ang-2 with rapid decline in renal function. A linear mixed-effects model analysis was used to identify the factors associated with a change of eGFR, with control for internal correlations and other covariates. All the variables in [Table 1](#pone-0108862-t001){ref-type="table"} were tested by univariate analysis and those variables with P-value less than 0.05, including diabetes, heart disease, eGFR, urine protein-creatinine ratio cut at 1 g/g, serum albumin, phosphate, calcium, hemoglobin and cholesterol levels, and age, gender, and ACEI/ARB use were selected for multivariate cox and logistic analyses and linear mixed-effects model analysis. Statistical analyses were conducted using SPSS 18.0 for Windows (SPSS Inc., Chicago, Illinois). Statistical significance was set at a two-sided p-value of less than 0.05.

10.1371/journal.pone.0108862.t001

###### The clinical characteristics of study subjects stratified by angiopoietin-2 quartile.

![](pone.0108862.t001){#pone-0108862-t001-1}

                                                                    Angiopoietin-2[a](#nt105){ref-type="table-fn"}                                                                                                                                                            
  ---------------------------------------------- ----------------- ------------------------------------------------ -------------------------------------------- ---------------------------------------------------- ------------------------------------------------------- ---------
  Demographics                                                                                                                                                                                                                                                                
  Age (year)                                         65.3±12.7                      62.2±13.6^\#^                    67.1±11.0[\*](#nt104){ref-type="table-fn"}                       65.9±12.2                                              66.0±13.2                          0.005
  Sex (male), n(%)                                   344(55.4)                         98(64.9)                                       89(56.7)                                         83(52.9)                              74(47.4)[\*](#nt104){ref-type="table-fn"}          0.01
  Smoke, n(%)                                        120(19.4)                         36(23.8)                                       22(14.0)                                         26(17.0)                                              36(23.1)                            0.1
  Alcohol,n(%)                                        49(7.9)                        20(13.2)^†^                                      13(8.3)                          7(4.6)[\*](#nt104){ref-type="table-fn"}                                9(5.8)                            0.03
  Cardiovascular disease, n(%)                       111(17.9)                         27(17.9)                                       20(12.7)                                         33(21.0)                                              31(19.9)                            0.2
  Cerebral vascular disease,n(%)                      55(8.9)                          11(7.3)                                        19(12.1)                                         15(9.6)                                                10(6.4)                            0.2
  Hypertension, n(%)                                 532(85.7)                        133(88.1)                                      138(87.9)                                        129(82.2)                                              132(84.6)                           0.3
  Diabetes mellitus, n(%)                            239(38.5)                         48(31.8)                                       57(36.3)                                         60(38.2)                                              74(47.4)                           0.03
  Hyperlipidemia, n(%)                               272(43.8)                         66(43.7)                                       77(49.0)                                         65(41.4)                                              64(41.0)                            0.4
  CKD cause, n(%)                                                                                                                                                                                                                                                             
  Chronic glomerulonephritis                         232(37.4)                         57(37.7                                        55(35.0)                                         61(38.9)                                              59(37.8)                            0.6
  Diabetic nephropathy                                180(29)                          41(27.2)                                       41(26.1)                                         47(29.9)                              51(32.7)[\*](#nt104){ref-type="table-fn"}        
  Others                                             209(33.7)                         53(35.1)                                       61(38.9)                                         49(31.2)                                              46(29.5)                         
  CKD stage 3 n(%)                                   146(23.5)                         45(29.8)                                       37(23.6)                                         37(23.6)                                              27(17.3)                           0.003
   4 n(%)                                            243(39.1)                         62(41.1)                                       72(45.9)                                         57(36.3)                                              52(33.3)                         
   5 n(%)                                            232(37.4)                         44(29.1)                                       48(30.6)                                         63(40.1)                                              77(49.4)                         
  Medications                                                                                                                                                                                                                                                                 
  Calcium channel blocker, n (%)                     341(54.9)                         80(53.0)                                       89(56.7)                                         78(49.7)                                              94(60.3)                            0.3
  β-blocker, n (%)                                   147(23.7)                         26(17.2)                                       28(17.8)                                         45(28.7)                           48(30.8)[\*](#nt104){ref-type="table-fn"} ^\#^        0.005
  ACEI/ARB, n (%)                                    353(56.8)                         89(58.9)                                       90(57.3)                                         85(54.1)                                              89(57.1)                            0.8
  Statin, n(%)                                       170(27.4)                         40(26.5)                                       47(29.9)                                         40(25.5)                                              43(27.6)                            0.8
  Laboratory parameters                                                                                                                                                                                                                                                       
  Blood urea nitrogen (mg/dl)                     41.1(30.0,60.0)                  34.9(26.9,52.8)                                38.7(29.5,55.1)                                  41.5(30.9,60.1)                     50.6(35.5,66.1)[\*](#nt104){ref-type="table-fn"} ^\#^   \<0.001
  Creatinine (mg/dl)                               2.9(2.1,5.0)                      2.8(1.9,4.4)                                   2.8(2.0,4.6)                                     3.0(2.2,5.6)                                          3.6(2.3,5.6)                         0.005
  eGFR (ml/min/1.73 m^2^)                            21.8±12.6                       24.7±13.9^†^                                    22.7±11.8                        20.7±12.3[\*](#nt104){ref-type="table-fn"}          18.9±11.9[\*](#nt104){ref-type="table-fn"} ^\#^      \<0.001
  Fasting sugar (g/dl)                              101(92,117)                       99(91,111)                                    100(94,119)                                      100(91,117)                         102(92,126)[\*](#nt104){ref-type="table-fn"} ^†^        0.3
  Glycated hemoglobin (%)                          5.8(5.5,6.7)                      5.7(5.4,6.4)                                   5.9(5.6,6.8)                                     5.7(5.4,6.4)                        6.1(5.5,7.2)[\*](#nt104){ref-type="table-fn"} ^†^      0.01
  Hemoglobin (g/dl)                                  10.9±2.1                       11.7±2.1^\#†^                    11.0±2.1[\*](#nt104){ref-type="table-fn"}        10.7±2.1[\*](#nt104){ref-type="table-fn"}           10.4±1.9[\*](#nt104){ref-type="table-fn"} ^\#^       \<0.001
  Albumin (g/dl)                                   4.1(3.9,4.3)                    4.2(4.0,4.4)^†^                                4.2(3.9,4.3)^†^                 4.0(3.8,4.3)[\*](#nt104){ref-type="table-fn"} ^\#^    4.0(3.7,4.2)[\*](#nt104){ref-type="table-fn"} ^\#^     \<0.001
  Phosphate (mg/dl)                                4.1(3.6,4.8)                      4.0(3.5,4.6)                                   4.0(3.6,4.6)                                     4.1(3.7,4.8)                                          4.3(3.8,5.1)                         0.02
  Calcium (mg/dl)                                     8.9±0.6                         9.1±0.6^†^                                      9.0±0.6                          8.8±0.6[\*](#nt104){ref-type="table-fn"}              8.8±0.8[\*](#nt104){ref-type="table-fn"}          \<0.001
  Uric acid (mg/dl)                                   7.6±1.9                          7.5±1.9                                        7.6±1.8                                          7.4±1.5                                                7.8±2.1                            0.2
  Cholesterol (mg/dl)                                 187±45                            192±47                                         190±40                                           182±45                                                188±46                             0.2
  Triglyceride (mg/dl)                              115(78,173)                      115(78,181)                                    112(82,172)                                      108(76,162)                                            126(79,181)                          0.6
  hsCRP (mg/L)                                     1.6(0.6,4.2)                      1.4(0.7,3.5)                                   1.5(0.5,3.7)                                     1.5(0.6,3.5)                      2.2(0.8,6.5)[\*](#nt104){ref-type="table-fn"} ^\#\ †^    0.03
  Parathyroid hormone (pg/ml)                       72(37,157)                        62(36,142)                                     63(35,120)                                       76(40,190)                                            106(33,191)                          0.2
  Urine protein-creatinine ratio \>1 g/g n (%)       275(49.3)                         57(41.0)                                       66(46.8)                                         70(49.6)                           82(59.9)[\*](#nt104){ref-type="table-fn"} ^\#^        0.01

Data are expressed as number (percentage) for categorical variables and mean±SD or median (25^th^, 75^th^ percentile) for continuous variables, as appropriate.

Conversion factors for units: eGFR in mL/min/1.73 m^2^ to mL/s/1.73 m^2^, ×0.01667 ; hemoglobin in g/dL to g/L, ×10; albumin in g/dL to g/L, ×10; calcium-phosphate product in mg^2^/dL^2^ to mmol^2^/L^2^, ×0.0806; cholesterol in mg/dL to mmol/L, ×0.02586; triglyceride in mg/dL to mmol/L, ×0.01129; uric acid in mg/dL toµmol/L, ×59.48.

Abbreviations: CKD, chronic kidney disease; ECW, extracellular water; ICW, intracellular water; TBW, total body water; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein.

\**P*\<0.05 compared with quartile 1; ^\#^ *P*\<0.05 compared with quartile 2; ^†^ *P*\<0.05 compared with quartile 3.

Angiopoietin-2 quartile cut at 1494.1, 1948.8, and 2593.1 pg/ml.

Results {#s3}
=======

Characteristics of Entire Cohort {#s3a}
--------------------------------

A total of 621 participants with CKD stages 3 to 5 were analyzed (mean eGFR 21.8 ml/min/1.73 m^2^, 146 in stage 3, 243 in stage 4, 232 in stage 5). The mean age was 65.3±12.7 years and 55.4% were male. [Table 1](#pone-0108862-t002){ref-type="table"} shows the baseline clinical characteristics stratified by quartiles of Ang-2, divided at 1494.1, 1948.8, and 2593.1 pg/ml. Of all patients, 532 (85.7%) were hypertensive and 239(38.5%)were diabetic mellitus. Pre-existing and documented heart disease and cerebral vascular disease were noted in 111(17.9%) and 55(8.9%) of patients respectively. The proportion of diabetes and β-blocker, serum blood urea nitrogen, phosphate and high-sensitivity C-reactive protein levels, and urine protein-creatinine ratio increased and eGFR, serum hemoglobin, calcium, and albumin levels decreased with Ang-2 quartiles.

10.1371/journal.pone.0108862.t002

###### Renal outcome of all subjects stratified by Angiopoietin-2 quartile.
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                                          Entire Cohort N = 621   Angiopoietin-2[a](#nt109){ref-type="table-fn"}                                                        
  -------------------------------------- ----------------------- ------------------------------------------------ ----------------- ----------------- ----------------- ---------
  Follow-up time (month)                        38.2±26.3                           43.8±28.1                         38.0±25.9         35.7±26.0         35.5±24.6       0.02
  No. of SCr measurement                        17 (9,27)                           18(8, 27)                         15(9,23)          15(9,24)          20(12,28)       0.01
  Doubling creatinine (n,%)                     165(26.6)                            35(23.2)                         37(23.6)          45(28.7)          48(30.8)         0.3
  eGFR decline (mL/min/1.73 m^2^/year)       −1.6(−3.3,−0.4)                      −1.3(−2.8,0.1)                   −1.8(−3.6,−0.9)   −1.8(−3.8,−0.6)   −1.5(−3.1,−0.2)    0.01
  Commencing dialysis (n,%)                     224(36.1)                            45(29.8)                         43(27.4)          59(37.6)          77(49.4)       \<0.001

Data are expressed as number (percentage) for categorical variables and median (25^th^, 75^th^ percentile) for continuous variables, as appropriate.

Conversion factors for units: eGFR in mL/min/1.73 m^2^ to mL/s/1.73 m^2^, ×0.01667.

Abbreviations: eGFR, estimated glomerular filtration rate.

Angiopoietin-2 quartile cut at 1494.1, 1948.8, and 2593.1 pg/ml.

Ang-2 and composite outcomes, either commencing dialysis or doubling creatinine {#s3b}
-------------------------------------------------------------------------------

Over a mean follow-up period of 38.2±26.3 months, 224 patients (36.1%) progressed to commencing dialysis (198 hemodialysis and 26 peritoneal dialysis, [Table 2](#pone-0108862-t002){ref-type="table"}). Seventy-one (11.4%) had mortality before reaching commencing dialysis. 18 (2.9%) were lost to follow-up (the mean follow-up period: 19.7±10.9 months), and no significant difference of proportion from quartile 1 to quartile 4 was found. A stepwise increase in the proportion of commencing dialysis from quartile 1 to quartile 4 was found (P-trend \<0.001). Of all subjects, 165 (26.6%) reached doubling creatinine during follow-up period, but there was no significant difference among Ang-2 quartiles. Kaplan-Meier survival curve showed a significant correlation between quartiles of Ang-2 and composite outcomes, either commencing dialysis or doubling creatinine ([Figure 1](#pone-0108862-g001){ref-type="fig"}). [Table 3](#pone-0108862-t003){ref-type="table"} presents the longitudinal associations between stepwise increases in Ang-2 levels and composite outcomes, either commencing dialysis or doubling creatinine. The unadjusted hazard ratio (HR) of composite outcomes was 1.96 (95% Confidence interval (CI): 1.43--2.69) for subjects of quartile 4 compared with those of quartile 1. The adjusted HR of composite outcomes was 1.53 (95% CI: 1.06--2.23) for subjects of quartile 4 compared with those of quartile 1. The longitudinal association between composite outcomes and stepwise increases in Ang-2 levels (P-trend  = 0.03).

10.1371/journal.pone.0108862.t003

###### The adjusted risks for composite outcomes, either commencing dialysis or doubling creatinine according to Angiopoietin-2 quartile.
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  Angiopoietin-2[a](#nt112){ref-type="table-fn"}    Composite outcomes   Commencing dialysis   Double creatinine                            
  ------------------------------------------------ -------------------- --------------------- ------------------- ------ ------------------ -----
  Quartile 1                                            Reference                                  Reference                 Reference      
  Quartile 2                                         1.42(0.95--2.13)           0.08           1.50(0.92--2.44)    0.01   1.43(0.83--2.47)   0.1
  Quartile 3                                         1.54(1.05--2.27)           0.02           1.73(1.10--2.71)    0.02   1.47(0.87--2.48)   0.1
  Quartile 4                                         1.53(1.06--2.23)           0.02           1.85(1.20--2.85)    0.02   1.47(0.87--2.45)   0.1

Abbreviations: CI, Confidence Interval; eGFR, estimated glomerular filtration rate.

Adjusted model: age, sex, cardiovascular disease, diabetes mellitus, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers use, estimated glomerular filtration rate, hemoglobin, serum calcium and cholesterol levels, log serum albumin and phosphate, and urine protein-creatinine ratio cut at 1 g/g.

Angiopoietin-2 quartile cut at 1494.1, 1948.8, and 2593.1 pg/ml.

![Kaplan-Meier survival curve for composite outcomes, either commencing dialysis or doubling creatinine of all subjects stratified by angiopoietin-2 quartile.](pone.0108862.g001){#pone-0108862-g001}

The unadjusted risk for commencing dialysis increased 2 fold (HR: 2.01, 95% CI: 1.39--2.90) for subjects of quartile 4 compared with those of quartile 1. The adjusted risk for commencing dialysis increased 85% (HR: 1.85, 95% CI: 1.20--2.85) for subjects of quartile 4 compared with those of quartile 1. The longitudinal association between commencing dialysis and stepwise increases in Ang-2 levels (P-trend  = 0.005). The unadjusted risk for doubling creatinine increased 89% (HR: 1.89, 95% CI: 1.21--2.93) for subjects of quartile 4 compared with those of quartile 1. However, there was no significant association of doubling creatinine with Ang-2 quartiles in adjusted model.

Ang-2, rapid decline in renal function and change in eGFR {#s3c}
---------------------------------------------------------

Eighty-five subjects (13.9%) had rapid decline in renal function. Patients of progressive decline in renal function (eGFR slope greater than 5 ml/min/1.73 m^2^/yr) were more likely to have higher level of Ang-2 than those of non-progressive decline in renal function (eGFR slope less than 5 ml/min/1.73 m^2^/yr) (median: 1944.9 *v.s.* 2066.0 pg/ml, P = 0.01). No significant different in baseline eGFR was found between the two groups. The adjusted risk for rapid decline in renal function increased 2.9 folds (OR: 2.96, 95% CI: 1.13--7.76) for subjects of quartile 4 compared with those of quartile 1 ([Table 4](#pone-0108862-t004){ref-type="table"}). [Table 4](#pone-0108862-t004){ref-type="table"} also shows the effect of study group on the change in eGFR in the linear mixed-effects model. The highest quartile of Ang-2 was associated with a significant decrease in eGFR over time as compared with the lowest quartile of Ang-2 (unstandardized coefficient β = −1.73, 95% CI: −3.34,−0.11, P = 0.03).

10.1371/journal.pone.0108862.t004

###### The adjusted risks for rapid decline in renal function and change of eGFR according to Angiopoietin-2 quartile.
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  Angiopoietin-2[a](#nt115){ref-type="table-fn"}    Rapid decline in renal function   Change of eGFR                       
  ------------------------------------------------ --------------------------------- ---------------- -------------------- ------
  Quartile 1                                                   Reference                                   Reference       
  Quartile 2                                               3.40(1.32--8.75)                0.01        −1.03(−2.63,0.57)    0.1
  Quartile 3                                               3.04(1.18--7.82)                0.02        −1.66(−3.25,−0.07)   0.03
  Quartile 4                                               2.96(1.13--7.76)                0.02        −1.73(−3.33,−0.11)   0.03

Abbreviations: CI, Confidence Interval; eGFR, estimated glomerular filtration rate.

Adjusted model: age, sex, cardiovascular disease, diabetes mellitus, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers use, estimated glomerular filtration rate, hemoglobin, serum calcium and cholesterol levels, log serum albumin and phosphate, , and urine protein-creatinine ratio cut at 1 g/g.

Angiopoietin-2 quartile cut at 1494.1, 1948.8, and 2593.1 pg/ml.

β expressed as ml/min/1.73 m^2^/year in eGFR.

Discussion {#s4}
==========

To our knowledge, this study is the first to evaluate the association of Ang-2 with adverse renal outcome in patients with stages 3--5 CKD over an observation period of 3 years. Ang-2 is associated with composite renal outcomes, either commencing dialysis or doubling creatinine after adjustment of baseline renal function and associated risk factors. Patients with quartile 3 or more of Ang-2 have more than 1.7 and 3.0-fold increase in risk for commencing dialysis and rapid decline in renal function respectively. Additionally, the linear mixed-effects model shows a more rapid decrease in eGFR over time in patients with quartile 3 or more of Ang-2 than those with quartile 1 of Ang-2. CKD patients with quartile 3(1948.8 pg/ml) or more of Ang-2 are more likely to reach the plateau of adverse renal outcome.

With regard to glomerular diseases, studies by Belinda et al. [@pone.0108862-Davis1] pointed out that increased glomerular expression of Ang-2 would tend to antagonize Ang-1-induced Tie-2 activation and destabilize capillaries and glomerular endothelia in podocin/Ang-2 transgene mice. There were significant increases in albuminuria and glomerular endothelial apoptosis, with significant decreases of both nephrin proteins and vascular endothelial growth factor A (VEGF-A), which were critical for maintenance of glomerular endothelia and glomerular filtration barrier integrity [@pone.0108862-Woolf1]--[@pone.0108862-Eremina1]. Besides, Seron et al. [@pone.0108862-Seron1] indicated a chronic loss of renal interstitial capillaries in human nephropathy, and Futrakul et al. [@pone.0108862-Futrakul1] suggested that an "anti-angiogenic environment" may exist in long-standing nephropathies. In clinical views, accumulating evidence shows that circulating Ang-2 is inversely related to eGFR and increases with advanced CKD and Ang-2 level is still increasing even after entering maintenance of dialysis [@pone.0108862-David2]. However, little is known about a clinical relationship between Ang-2 and adverse renal outcome. The present study identifies that increased circulating Ang-2 is associated with risks for commencing dialysis and rapid decline in renal function in patients not on dialysis, and Ang-2 is an independent predictor of adverse renal outcome in CKD cohort.

Consistent with reports by Chang et al. [@pone.0108862-Chang2], our results also showed a significant association of circulating Ang-2 with hypoalbuminemia and high-sensitivity C-reactive protein (hs-CRP), as indicators of malnutrition-inflammation. Fiedler et al. identified Ang-2 as an autocrine regulator of endothelial cell inflammatory responses and Ang-2 acts as a switch of vascular responsiveness exerting a permissive role for the activities of proinflammatory cytokines [@pone.0108862-Chong1]. Ang-2 serves the link between angiogenic and inflammatory pathway, Ang-2 signaling between cellular elements in renal fibrosis, including endothelial cells, pericytes, myofibroblasts, and macrophages [@pone.0108862-Woolf1]. Meanwhile, CKD has been regarded as a disease with persistent and low-grade inflammation, and our previous study indicated that inflammation is an independent predictor of rapid decline in renal function in CKD cohort [@pone.0108862-Tsai1]. Hence, there might be an interaction among Ang-2, inflammation and rapid decline in renal function. The findings of our subgroup analysis show that elevated Ang-2 is independently associated with risk for maintenance dialysis in subjects of less than the median of hsCRP (1.56 mg/l; HR for log Ang-2: 4.80, 95%CI: 1.68--13.76). In addition, there is a significant association between Ang-2 and maintenance dialysis in subjects of serum albumin above 3.5 g/dl (HR for log Ang-2: 2.15, 95%CI: 1.05--4.38). Thus, circulating Ang-2 is possibly a significant risk factor for adverse renal outcome independent of malnutrition-inflammation.

Increased endothelial Ang-2 secretion is stimulated by exogenous stimuli such as angiotensin II, tumor necrosis factor-α, hypoxia, and reactive oxygen species, which are characteristics in CKD progression [@pone.0108862-Fiedler1]. Endothelial injury in glomerular vasculature may induce endothelial Ang-2 secretion, and meanwhile, increased Ang-2 may lead to glomerular albuminuria through endothelial injury. It is difficult to evaluate whether increased Ang-2 is a cause or consequence of CKD progression [@pone.0108862-Fiedler1]. Because of this complicated interaction among Ang-2, traditional risk factors, and CKD, we adjusted associated risk factors for rapid decline in renal function in multivariate analysis. We also performed subgroup analysis in different CKD stages, but the results did not consistent at all ([Figure S1](#pone.0108862.s001){ref-type="supplementary-material"}--[S3](#pone.0108862.s003){ref-type="supplementary-material"}). It is probably related to relative small number of subgroup and short observation period. We need further study to evaluate whether these risk factors are modifiers or confounders in association of Ang-2 and commencing dialysis. Besides, to consider the influence of competing risk of death on commencing dialysis, we performed further analysis, and the results are consistent (HR for quartile 4 compared with quartile 1: 1.85 (95% CI: 1.20--2.86). Our findings show a strong association of Ang-2 and adverse renal outcome and emphasize its importance as a predictor in CKD cohort.

Despite exogenous stimuli, Ang-2 was excreted by factors influencing the exocytosis of Weibel-Palade body, including thrombin, histamine, serotonin, vascular endothelial growth factor (VEGF) and epinephrine [@pone.0108862-Rondaij1]. Therefore, it could be influenced by medication. In this study, no significant difference of medication was found among Ang-2 quartiles except for β-blocker. In post hoc multiple comparisons, subjects of Ang-2 quartile 4 had higher proportion of using β-blocker than those of Ang-2 quartile 1 and 2. The reason might be related to blood pressure control or arrhythmia. The present study has a limitation that we did not record blood pressure and arrhythmia at enrollment. In late CKD, patients usually need three or more kinds of anti-hypertension medicines to keep adequate blood pressure and use β-blocker for arrhythmia. It is probably the reason for the different proportion of β-blocker usage. Contrarily, β-blocker promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway [@pone.0108862-Rengo1]. Hence, higher level of Ang-2 in late CKD patients may be partially related to long term usage of β-blocker. We also add β-blocker usage into multivariate analysis, and Ang-2 is still associated with adverse renal outcome. Further study is needed to investigate the relationship of ang-2 and β-blocker.

Ang-2 is usually elevated in diabetes and associated with endothelial dysfunction, which leads to microvascular and macrovascular complications [@pone.0108862-Lim1], . The pathophysiological mechanisms by which Ang-2 participates in rapid decline in renal function are complicated and include various pathways, such as arterial stiffness or oxidative stress [@pone.0108862-David2], [@pone.0108862-Chang2]. Our results show an association of Ang-2 quartiles with the proportion of diabetes, but no correlation between Ang-2 quartiles and glycated hemoglobin in patients with integrated CKD care program. Although average sugar level is under strict control, some patients still reach adverse renal outcome. Accumulating evidence indicates that strict glycemic control might not be enough to prevent rapid decline in renal function in late CKD [@pone.0108862-Shurraw1]. It is probably that Ang-2 is associated with adverse renal outcome beyond the effects of diabetes. Additionally, patients with cardiovascular disease, cerebrovascular disease or hypertension are more likely to have higher circulating Ang-2 level [@pone.0108862-Nadar1], [@pone.0108862-Chong1], [@pone.0108862-Lee1], [@pone.0108862-Cui1]. Ang-2 has been associated with cardiovascular markers, such as cell adhesion molecules and inflammation [@pone.0108862-Shroff1], and increases endothelial apoptosis, enhances myocardial microvascular inflammation, and promotes cardiac fibrosis [@pone.0108862-Chen1]. Although there was no different proportion of cardiovascular disease, cerebrovascular disease and hypertension in Ang-2 quartiles at baseline in our cohort, Ang-2 might be probably associated with cardiovascular events in the future. Thus, further study is needed to evaluate the relationship between Ang-2 and cardiovascular outcome.

On the other hand, previous study reported a significant correlation between Ang-2 and asymmetric dimethylarginine (ADMA), as the nitric oxide (NO) synthase inhibitor [@pone.0108862-David2]. CKD has been regarded as a NO-deficient state, and the oxidative stress leads to not only renal function decline, but also adverse cardiovascular sequelae [@pone.0108862-Wever1], [@pone.0108862-Baylis1]. Thus, ADMA is not only a uremic toxin, but also a strong marker of endothelial dysfunction and atherosclerosis [@pone.0108862-Kielstein1]. Sascha et al. speculated that the increased Ang-2 levels might reveal excess Weibel-Palade body exocytosis as a consequence of decreased NO bioavailability in the presence of high ADMA levels [@pone.0108862-David2]. Although further in vivo and in vitro studies are needed to evaluate the interaction between Ang-2 and NO bioavailability, it could possibly explain one of the potential mechanisms responsible for the association between Ang-2 and adverse renal outcome.

This study has some limitations that must be considered. The major uncertainty is whether circulating Ang-2 is biologically active in CKD patients. The biological implication of Ang-2 changes in the range observed in our patients is still unknown. Besides, Ang-2 was measured once at enrollment. The effect of the time-varying Ang-2 levels might be underestimated. Additionally, the mechanism contributing to the association between increased circulating Ang-2 and rapid decline in renal function has not been well-explored. Further study is needed to investigate the pathogenic link between Ang-2 and rapid decline in renal function.

In conclusion, our study demonstrates that elevated circulating Ang-2 is associated with increased risks for adverse renal outcome in stages 3--5 CKD patients. Future studies will be necessary to evaluate the pathogenic role of Ang-2 in renal progression, and to establish the beneficial renal function by targeting Ang-2.
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###### 

**Adjusted hazard ratios (HRs) of commencing dialysis for Angiopoietin-2 (Ang-2) quartile 4 compared with Ang-2 quartile 1 in CKD stages 3--5 subjects stratified by proteinuria, high sensitivity c-reactive protein (hsCRP), serum albumin and angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB) usage.** Ratios were adjusted for age, sex, cardiovascular disease, diabetes mellitus, ACEI/ARB usage, estimated glomerular filtration rate, hemoglobin, serum calcium and cholesterol levels, log serum albumin and phosphate, and urine protein-creatinine ratio cut at 1 g/g. The median values of serum albumin and hsCRP are 3.8 g/dl and 1.5 mg/l respectively.

(TIF)

###### 

Click here for additional data file.

###### 

**Adjusted hazard ratios (HRs) of commencing dialysis for Angiopoietin-2 (Ang-2) quartile 4 compared with Ang-2 quartile 1 in CKD stages 3--4 subjects stratified by proteinuria, high sensitivity c-reactive protein (hsCRP), serum albumin and angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB) usage.** Ratios were adjusted for age, sex, cardiovascular disease, diabetes mellitus, ACEI/ARB usage, estimated glomerular filtration rate, hemoglobin, serum calcium and cholesterol levels, log serum albumin and phosphate, and urine protein-creatinine ratio cut at 1 g/g. The median values of serum albumin and hsCRP are 3.8 g/dl and 1.5 mg/l respectively.

(TIF)

###### 

Click here for additional data file.

###### 

**Adjusted hazard ratios (HRs) of commencing dialysis for Angiopoietin-2 (Ang-2) quartile 4 compared with Ang-2 quartile 1 in CKD stage 5 subjects stratified by proteinuria, high sensitivity c-reactive protein (hsCRP), serum albumin and angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB) usage.** Ratios were adjusted for age, sex, cardiovascular disease, diabetes mellitus, ACEI/ARB usage, estimated glomerular filtration rate, hemoglobin, serum calcium and cholesterol levels, log serum albumin and phosphate, and urine protein-creatinine ratio cut at 1 g/g. The median values of serum albumin and hsCRP are 3.8 g/dl and 1.5 mg/l respectively.

(TIF)

###### 

Click here for additional data file.
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